Navigation Links
U.S. Food and Drug Administration Approves ORENCIA(R) (abatacept) for the Treatment of Moderate-to-Severe Polyarticular Juvenile Idiopathic Arthritis (JIA) in Patients Six Years and Older
Date:4/8/2008

- ORENCIA is a First-in-Class Biologic Treatment Option Now Available for

Use in Pediatric Patients with JIA(1,2) -

PRINCETON, N.J., April 8, 2008 /PRNewswire-FirstCall/ -- Bristol-Myers Squibb Company (NYSE: BMY) today announced that the U.S. Food and Drug Administration (FDA) has approved ORENCIA(R) (abatacept) for reducing signs and symptoms in pediatric patients six years and older with moderately to severely active polyarticular juvenile idiopathic arthritis (JIA). ORENCIA may be used as monotherapy or concomitantly with methotrexate (MTX). ORENCIA should not be administered concomitantly with tumor necrosis factor (TNF) antagonists and is not recommended for use concomitantly with other biologic rheumatoid arthritis (RA) therapy, such as anakinra. This new indication for ORENCIA provides significant evidence of its durable efficacy and long-term safety in pediatric patients, including those initiating biologic therapy for the first time. The safety and efficacy of ORENCIA in JIA were assessed in a three-part study through one year. The approval of ORENCIA in JIA represents the ongoing commitment of Bristol-Myers Squibb in this therapeutic area.

"In a JIA clinical trial, ORENCIA provided meaningful and sustained improvements in this patient population across three major sub-types of JIA through one year," said Edward H. Giannini, M.Sc., Dr.P.H., Professor of Pediatrics, Division of Rheumatology, Cincinnati Children's Hospital Medical Center, OH.

The approval is based on the AWAKEN (Abatacept Withdrawal study to Assess efficacy and safety in Key Endpoints in juvenile idiopathic arthritis Not responding to current treatment) trial, which evaluated the efficacy and safety of ORENCIA(R) (abatacept) in
'/>"/>

SOURCE Bristol-Myers Squibb Company
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related medicine technology :

1. Ortho Biotech Statement on U.S. Food and Drug Administration Oncologic Drugs Advisory Committee Vote
2. U.S. Food and Drug Administration Approves ABILIFY(R) (aripiprazole) for the Acute Treatment of Manic and Mixed Episodes Associated With Bipolar I Disorder in Pediatric Patients (10 to 17 Years of Age)
3. Northwestern Offers Clinical Research and Regulatory Administration Graduate Certificate Program
4. Supplemental New Drug Application for PREZISTA(TM) Submitted to U.S. Food and Drug Administration
5. Biological Psychiatry Publishes Study Showing VYVANSE Demonstrated Significant Efficacy for Treatment of ADHD for up to 12 Hours After Administration
6. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
7. FDA Approves XYZAL(R) (levocetirizine dihydrochloride) Oral Solution for the Relief of Seasonal and Year Round Allergies and Chronic Idiopathic Urticaria
8. FDA Approves MiddleBrooks Amoxicillin PULSYS for Pharyngitis/Tonsillitis in Adolescents and Adults
9. European Commission Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for Virologically Suppressed Adults With HIV-1 Infection
10. FDA Approves Cymbalta(R) for Maintenance Treatment of Major Depressive Disorder
11. Health Canada Approves ATRIPLA(R) (efavirenz 600 mg/emtricitabine 200 mg/ tenofovir disoproxil fumarate 300 mg), the First Once-Daily Single Tablet Regimen for HIV
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)...  With a vision to ensure safety and ... Pharmaceutical and Biotech manufacturer selects and implements the ... to protect their animal health brand.  ... Photo - http://photos.prnewswire.com/prnh/20141021/153439 ... by the Xyntek and Antares solution is an ...
(Date:10/22/2014)... ST. LOUIS , Oct. 21, 2014 /PRNewswire-USNewswire/ ... are often subtle or unnoticed, but new technology, ... patient outcomes and leading to earlier detection of ... now affects 29 million Americans. If left untreated, ... or even blindness. Recently, optometric ...
(Date:10/22/2014)... WESTMINSTER, Colo. , Oct. 22, 2014   ... class of infusion systems designed to maximize targeted delivery ... is pleased to announce that oncologist John R. ... Norris Comprehensive Cancer Center, and surgical oncologist Steven ... Center have joined the Company,s Scientific Advisory Board (SAB).  ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 2Technology Advancements Enhance Early Detection of Eye Diseases Associated with Diabetes 3Surefire Medical's Scientific Advisory Board Expands, Broadens Clinical Trial Expertise 2
... Findings from a,trial of the accuracy of CT ... pre-cancerous polyps and colorectal cancers,coordinated by the American ... issues for the public about colorectal cancer,screening using ... need for follow-up,with complete colonoscopy in many cases, ...
... The Department of,Justice announced today that it will ... Cancer (CRC) to develop and publicize model contract ... The Department said,the language is not likely to ... efficiency in contract negotiations, potentially reducing costs,and shortening ...
Cached Medicine Technology:Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 2Despite Advances in the Accuracy of CT Colonography in Detecting Polyps, Digestive Health Experts Urge Patients to Consider Risks and Realities 3Justice Department Will Not Oppose CEO Roundtable on Cancer's Proposal 2
(Date:10/25/2014)... Raleigh, NC (PRWEB) October 25, 2014 ... patient who continued to receive pemetrexed (Alimta), after his ... to read the full story , just posted on ... study from Uji Tokushukai Medical Center in Japan suggests ... for mesothelioma patients who cannot tolerate higher ...
(Date:10/25/2014)... Steven Reinberg HealthDay Reporter ... virus that causes common cold sores -- herpes simplex -- ... Swedish researchers suggest. In fact, being a carrier of ... Alzheimer,s disease, the researchers found. "The identification of ... disorder is a breakthrough," said lead researcher Dr. Hugo Lovheim, ...
(Date:10/25/2014)... Oct. 23, 2014 (HealthDay News) -- A large influx ... Africa is to avoid tens of thousands of deaths ... University researchers predict. Using a specially designed ... of the outbreak in just one densely populated county ... capital city of Monrovia. The researchers said that ...
(Date:10/25/2014)... 2014 (HealthDay News) -- October,s shorter, darker days can ... disorder, according to an expert. People affected ... overly tired, lack motivation and even have trouble getting ... to suicide, said Dr. Angelos Halaris, a professor in ... University Chicago Stitch School of Medicine. "Seasonal affective ...
(Date:10/22/2014)... On October 22, CBS will air ... diseases both fictional and real. The Charles E ... committed to advocacy and philanthropy in the battle against ... opportunity to impart truth and clarity about this misunderstood ... many misconceptions about Morgellons Disease (MD) and ...
Breaking Medicine News(10 mins):Health News:New Report Illustrates Extended Mesothelioma Survival with “Maintenance Therapy”, According to Surviving Mesothelioma 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 2Health News:Studies Link Cold Sore Virus to Alzheimer's Risk 3Health News:Experts Predict 'Catastrophic' Ebola Epidemic in West Africa if Aid Delayed 2Health News:Dark Days Here for Folks With Seasonal Depression 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 2Health News:CBS’ Criminal Minds takes aim at skin disease with Morgellons in the Mix 3
... ... to the position of Chief Operating Officer. She brings to the position more than ... business process review, performance management, organizational development, and quality assurance. , ... Columbus, OH (Vocus) September 11, 2009 ...
... , , , , ... costs are the single biggest economic concern facing American businesses, according to ... , Nearly 90% of those polled cite health care costs ... or energy costs. , , Without reform, 86% of ...
... from electronic assistance, researchers say , FRIDAY, Sept. 11 ... people can, new research suggests. , The findings may ... hard-of-hearing learn to read lips, according to researchers from ... compared the accuracy of an automated lip-reading machine to ...
... Reducing Americans, average intake of sodium to the amount recommended ... $18 billion annually in avoided health care costs and improve ... a new RAND Corporation study. The study estimates that ... high blood pressure nationally and extend the lives of thousands ...
... Sept. 11 Nuvilex, Inc. (OTC Bulletin Board: NVLX), ... partner, has informed the company that Reme-Flu(TM) has been ... for helping to prevent and treat flu-like symptoms resulting ... consists of a two-part protocol. Part one contains ...
... , , MISSISSAUGA, Ontario, Sept. 11 ... into an agreement with The Investor Relations Group, Inc. ("IRG"), pursuant ... services for the Company in accordance with the terms of the ... inquiries directly to IRG. , , "We are ...
Cached Medicine News:Health News:CBCA Administrators, Inc. Promotes Cindy Sonnen to Chief Operating Officer 2Health News:Poll Shows Solid Business Support for Health Care Reform 2Health News:Poll Shows Solid Business Support for Health Care Reform 3Health News:Computers Might Make Learning Lip Reading Easier 2Health News:Lowering sodium consumption could save US $18 billion annually in health costs, study finds 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 2Health News:Nuvilex, Inc. Announces Reme-Flu(TM) as Trade Name for All-Natural Flu Remedy Formula 3Health News:JAG Media Holdings, Inc. Announces Agreement with The Investor Relations Group, Inc. 2
The soft silicone design promotes patient comfort. , ,Bivona® laryngectomy tubes feature a soft compliant silicone design for patient comfort....
Manufactured with a radiopaque line running down the length of the tube, position can be easily visualized by x-ray....
... vertical length tubes are often indicated ... stenosis, and tracheal malacia. Available in ... two independently inflatable cuffs. Greater flexibility ... since cuff sites can be alternated, ...
... It has been estimated that in excess ... special needs that require a specialized tracheostomy ... Tubes are soft, flexible, and can adapt ... patient including those requiring:, extra horizontal ...
Medicine Products: